Skip to content


Volume 3 Supplement 1


  • Poster presentation
  • Open Access

Hemodynamics effects of adrecizumab in sepsis rat

  • 1, 2, 3,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1 and
  • 1, 2, 3
Intensive Care Medicine Experimental20153 (Suppl 1) :A618

  • Published:


  • Septic Shock
  • Severe Sepsis
  • Mean Arterial Pressure
  • Hemodynamic Effect
  • Vascular Dysfunction


Sepsis and septic shock still represent major health issues, with persisting high morbidity and mortality rates in critically ill patients. Cardiac dysfunction[1] occurs frequently during severe sepsis.

Adrenomedullin (ADM) has been identified as a key mediator in vascular tone regulation[1]. A newly developed anti-ADM antibody Adrecizumab (ADZ) may improve hemodynamic dysfunction during resuscitated murine, cecal ligation and puncture (CLP)-induced septic shock[2].


To determine the beneficial role of ADZ on hemodynamic impairment in a rat model of acute sepsis.


For induction of polymicrobial sepsis, cecal ligation and puncture (CLP)[3] was performed in Wistar male rats. ADZ (2 mg/kg) was injected IV 24 h after the surgery. There were 7 animals per group. Invasive blood pressure and cardiac function (by echocardiography) were assessed until 2 hours after ADZ injection. Statistical analysis was performed with 2 ways ANOVA.


Septic rats had lower mean arterial pressure (MAP) (p < 0.0001) 24 h after surgery (at baseline) compared to sham. Septic animas with ADZ had a trend to have a greater MAP. A transient decrease of SF was observed 15 min and 1 h after injection of ADZ (p = 0.05). On the other hand cardiac output seems to be increased by ADZ (p = 0.61).


During sepsis in rats, treatment by ADZ seems to have a beneficial effect on cardiac and vascular dysfunction. These preliminary results need to be confirmed in preclinical and clinical studies.
Figure 1
Figure 1

[Mean arterial pressure]

Grant Acknowledgment


Authors’ Affiliations

Inserm, UMR 942 Paris, France
Department of Anesthesiology and Critical Care and Burn Center, GH Lariboisière Saint-Louis, APHP, Paris, France
University Paris VII Denis Diderot, Paris, France


  1. Nishio K, et al: Critical Care Medicine. 1997, 25 (6): 953-7. 10.1097/00003246-199706000-00010.PubMedView ArticleGoogle Scholar
  2. Struck , et al: Intensive Care Med Expe. 2013, 1: 3-10.1186/2197-425X-1-3.View ArticleGoogle Scholar
  3. Rittirsch , et al: Nature Protocols. 2009, 4: 31-36. n°1PubMedPubMed CentralView ArticleGoogle Scholar